The Effect of the Classical TSPO Ligand PK 11195 on In Vitro Cobalt Chloride Model of Hypoxia-like Condition in Lung

Rula Amara1, Nidal Zeineh1, Sheelu Monga1

  • 1Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel.

Biomolecules
|October 27, 2022
PubMed

Insights

The mitochondrial translocator protein (TSPO) ligand PK 11195 protects lung and brain cells from hypoxia-induced damage. This suggests TSPO ligands may treat certain hypoxia-related diseases.

Area of Science:

  • Cellular and Molecular Biology
  • Neuroscience
  • Pharmacology

Background:

  • Mitochondrial translocator protein (TSPO) regulates apoptosis via reactive oxygen species (ROS) and mitochondrial membrane potential (Δψm).
  • Hypoxia induces cellular damage, impacting lung and brain tissues.

Purpose of the Study:

  • To investigate the protective effects of the TSPO ligand PK 11195 against CoCl2-induced hypoxia-like effects in H1299 lung and BV-2 microglial cells.
  • To evaluate TSPO's role in mitigating hypoxia-related cellular damage.

Main Methods:

  • In vitro exposure of H1299 and BV-2 cells to cobalt chloride (CoCl2) to mimic hypoxia.
  • Assessment of cell viability, cardiolipin peroxidation, Δψm, and apoptosis.
  • Treatment with PK 11195 to evaluate its protective effects.

Main Results:

  • CoCl2 exposure decreased cell viability, increased cardiolipin peroxidation, depolarized Δψm, and induced apoptosis in H1299 cells.
  • PK 11195 pretreatment significantly protected against CoCl2-induced cellular damage.
  • CoCl2 induced dose-dependent alterations in BV-2 cells, which were attenuated by PK 11195.

Conclusions:

  • The TSPO ligand PK 11195 demonstrates significant protective capacity against CoCl2-induced cellular damage in both non-neuronal and brain cell lines.
  • TSPO ligands may offer a novel therapeutic strategy for hypoxia-related lung and brain diseases, particularly in cases resistant to conventional treatments.

Related Concept Videos